[HTML][HTML] Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta …
W Zhang, Y Wei, D Yu, J Xu, J Peng - BMC cancer, 2018 - Springer
Background The first-generation epidermal growth factor receptor tyrosine kinase inhibitors
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis
W Zhang, Y Wei, D Yu, J Xu, J Peng - BMC cancer, 2018 - pubmed.ncbi.nlm.nih.gov
Background The first-generation epidermal growth factor receptor tyrosine kinase inhibitors
gefitinib and erlotinib have both been proven effective for treating advanced non-small cell …
gefitinib and erlotinib have both been proven effective for treating advanced non-small cell …
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis
W Zhang, Y Wei, D Yu, J Xu, J Peng - BMC Cancer, 2018 - go.gale.com
Background The first-generation epidermal growth factor receptor tyrosine kinase inhibitors
gefitinib and erlotinib have both been proven effective for treating advanced non-small cell …
gefitinib and erlotinib have both been proven effective for treating advanced non-small cell …
[HTML][HTML] Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta …
W Zhang, Y Wei, D Yu, J Xu, J Peng - BMC Cancer, 2018 - ncbi.nlm.nih.gov
Background The first-generation epidermal growth factor receptor tyrosine kinase inhibitors
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis.
W Zhang, Y Wei, D Yu, J Xu, J Peng - BMC Cancer, 2018 - europepmc.org
Background The first-generation epidermal growth factor receptor tyrosine kinase inhibitors
gefitinib and erlotinib have both been proven effective for treating advanced non-small cell …
gefitinib and erlotinib have both been proven effective for treating advanced non-small cell …
[HTML][HTML] Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta …
W Zhang, Y Wei, D Yu, J Xu, J Peng - BMC Cancer, 2018 - bmccancer.biomedcentral.com
The first-generation epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib have both been proven effective for treating advanced non–small cell lung cancer …
erlotinib have both been proven effective for treating advanced non–small cell lung cancer …
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis.
W Zhang, Y Wei, D Yu, J Xu, J Peng - BMC Cancer, 2018 - search.ebscohost.com
Abstract < bold> Background: </bold> The first-generation epidermal growth factor
receptor tyrosine kinase inhibitors gefitinib and erlotinib have both been proven effective for …
receptor tyrosine kinase inhibitors gefitinib and erlotinib have both been proven effective for …
[PDF][PDF] Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis
W Zhang, Y Wei, D Yu, J Xu, J Peng - 2018 - bmccancer.biomedcentral.com
Background: The first-generation epidermal growth factor receptor tyrosine kinase inhibitors
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …